ArticlePLoS neglected tropical diseases2017
Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles.
Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Diagnostic accuracy of novel Biocredit species-specific LDH-based immunochromatographic assay for Plasmodium falciparum and Plasmodium vivax detection: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Parasitaemia and fever in uncomplicated Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Elevations in D-dimer levels in patients with Plasmodium infections: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Facilitating the use of the target product profile in academic research: a systematic review.Journal of translational medicine · 2024Pooled it
- Target Product Profiles for medical tests: a systematic review of current methods.BMC medicine · 2020Pooled it
- Analytical Sensitivity Analysis and Clinical Impact Modeling of Rapigen Rapid Diagnostic Tests for Malaria.The American journal of tropical medicine and hygiene · 2024Article
- Spatiotemporal Epidemiology of Malaria in India from 2007 to 2022.The American journal of tropical medicine and hygiene · 2024Article
- Article
- A Review of the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria.Pathogens (Basel, Switzerland) · 2023Review
- Vivax malaria: a possible stumbling block for malaria elimination in India.Frontiers in public health · 2023Review
- Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication.Tropical diseases, travel medicine and vaccines · 2022Review
- Proteomic Analysis of Urine from Patients withTropical medicine and infectious disease · 2022Article
- Comparison of total immunoglobulin G antibody responses to different protein fragments of Plasmodium vivax Reticulocyte binding protein 2b.Malaria journal · 2022Article
- Ultrasensitive CRISPR-based diagnostic for field-applicable detection ofProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Matching Development of Point-of-Care Diagnostic Tests to the Local Context: A Case Study of Visceral Leishmaniasis in Kenya and Uganda.Global health, science and practice · 2020Article
- Association between the proportion of Plasmodium falciparum and Plasmodium vivax infections detected by passive surveillance and the magnitude of the asymptomatic reservoir in the community: a pooled analysis of paired health facility and community data.The Lancet. Infectious diseases · 2020Article
- Plasmodium vivax liver stage assay platforms using Indian clinical isolates.Malaria journal · 2020Article
- Plasmodium vivax in the Era of the Shrinking P. falciparum Map.Trends in parasitology · 2020Review
- Development and validation of serological markers for detecting recent Plasmodium vivax infection.Nature medicine · 2020Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 15 institutions in 12 countries.
Funding
Abstract
The global prevalence of malaria has decreased over the past fifteen years, but similar gains have not been realized against Plasmodium vivax because this species is less responsive to conventional malaria control interventions aimed principally at P. falciparum. Approximately half of all malaria cases outside of Africa are caused by P. vivax. This species places dormant forms in human liver that cause repeated clinical attacks without involving another mosquito bite. The diagnosis of acute patent P. vivax malaria relies primarily on light microscopy. Specific rapid diagnostic tests exist but typically perform relatively poorly compared to those for P. falciparum. Better diagnostic tests are needed for P. vivax. To guide their development, FIND, in collaboration with P. vivax experts, identified the specific diagnostic needs associated with this species and defined a series of three distinct target product profiles, each aimed at a particular diagnostic application: (i) point-of-care of acutely ill patients for clinical care purposes; (ii) point-of-care asymptomatic and otherwise sub-patent residents for public health purposes, e.g., mass screen and treat campaigns; and (iii) ultra-sensitive not point-of-care diagnosis for epidemiological research/surveillance purposes. This report presents and discusses the rationale for these P. vivax-specific diagnostic target product profiles. These contribute to the rational development of fit-for-purpose diagnostic tests suitable for the clinical management, control and elimination of P. vivax malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.